Skip to main content
OpenTrials
Active, Not Recruiting

NCT Number: NCT05182632

Tele-rehabilitation Group Program for Urinary Incontinence in Older Women

The recommended treatment for urinary incontinence (UI) in women is individualized pelvic floor muscle training (PFMT), a costly and resource-intensive approach; one Canada is currently unable to meet.

A recent non-inferiority randomized controlled trial just confirmed that group-based PFMT is equally effective but less resource-intensive (more cost-effective) than individual PFMT to treat UI in older women (ClinicalTrials.gov Identifier: NCT02039830). In times of COVID-19 however, with the Quebec, Canada's public health authorities preventing gatherings to stop the virus' spread, the potential of in-person group approaches is temporarily limited. It is thus important to develop innovative ways to deliver this first-line treatment remotely, particularly for those confined at home for whom UI can have a detrimental impact on physical health and quality of life. Ensuring an online option for group-based PFMT would also allow to increase the accessibility of UI treatment for women living in rural or remote areas in Canada, where pelvic floor rehabilitation services are not available or scarce.

To this end, this study will assess the feasibility, acceptability and effects of a tele-rehabilitation PFMT group program for UI in older women.

Active, Not Recruiting

This study is active but is not currently recruiting participants.

Key information

Conditions

Urinary Incontinence Female Urogenital Diseases Female Urogenital Diseases and Pregnancy Complications Lower Urinary Tract Symptoms Male Urogenital Diseases Pathological Conditions, Signs and Symptoms Signs and Symptoms Urinary Incontinence, Stress Urinary Stress Incontinence Urination Disorders Urogenital Diseases Urologic Diseases Urological Manifestations

Age range

65 year and older

Sex eligibility

Female

Study type

Interventional

Phase

Not applicable

Primary location

Centre de recherche de l'Institut universitaire de gériatrie de Montréal (CRIUGM)

Montreal, Quebec, H3W 1W4, Canada

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • 65 or older, as older women will show a particular genitourinary profile compared with younger women, notably due to menopause. This age cut-off was used in other studies in UI;
  • Ambulatory (able to walk, move about safely and autonomously without any mobility device);
  • Describe a pattern of stress/mixed UI, confirmed using the Questionnaire for Incontinence Diagnosis (QUID);
  • Have at least three urinary leakage per week, persisting for 3 months or more;
  • Understand French or English instructions;
  • Report no important cognitive deficit (determined with a Mini-Mental State Evaluation (MMSE) score of 24/30 or more);
  • Have an internet access; and
  • Able to give informed consent and complete a gynecological examination and fill 7-day bladder diaries and questionnaires.

Exclusion criteria

  • Present risk factors known to interfere with the effects of PFMT or with the PFM evaluation, including chronic constipation (as defined by the International Working Committee for Chronic Constipation), important pelvic organ prolapse (Baden-Walker score > stage 2), or any other comorbidities with a potential impact on the treatment (i.e. cognitive impairment, diabetes, active cancer, respiratory or cardiovascular conditions, etc);
  • Currently taking medication for UI or medications affecting skeletal muscles;
  • Considered obese with a body mass index (BMI) over 35;
  • Had an active urinary or vaginal infection in the past 3 months;
  • Underwent a change in hormonal replacement therapy in the past 6 months;
  • Received pelvic floor physiotherapy treatment or surgery for UI or pelvic organ prolapse in the past year

Treatment and study plan

Group pelvic floor telerehabilitation

Behavioral

Multimodal group physiotherapy: 12 weeks of weekly group physiotherapy treatments including education and pelvic floor muscle exercises delivered online + home exercise program

Primary outcomes

  1. number of UI episodes

    Time frame: at recruitment (PRE1)

    number of UI episodes, evaluated with a 7-day bladder diary

  2. number of UI episodes

    Time frame: just before the intervention (PRE2)

    number of UI episodes, evaluated with a 7-day bladder diary

  3. number of UI episodes

    Time frame: immediately after the 12-week intervention (POST)

    number of UI episodes, evaluated with a 7-day bladder diary

  4. number of UI episodes

    Time frame: 6 months after the end of the 12-week intervention (FOLLOW-UP)

    number of UI episodes, evaluated with a 7-day bladder diary

  5. percentage reduction (%) in the number of UI episodes

    Time frame: at recruitment (PRE1), just before the intervention (PRE2), immediately after the 12-week intervention (POST), 6 months after the end of the 12-week intervention (FOLLOW-UP)

    percentage reduction (%) in the number of UI episodes, evaluated with a 7-day bladder diary

Secondary outcomes

  1. urinary symptoms and degree to which UI-associated symptoms are troubling or bothersome

    Time frame: at recruitment (PRE1)

    urinary symptoms and degree to which UI-associated symptoms are troubling or bothersome, evaluated using the International Consultation on Incontinence Questionnaire module on UI symptoms (ICIQ-UI) short form (0-21 overall score, with higher scores indicating more sever symptoms)

  2. urinary symptoms and degree to which UI-associated symptoms are troubling or bothersome

    Time frame: just before the intervention (PRE2)

    urinary symptoms and degree to which UI-associated symptoms are troubling or bothersome, evaluated using the International Consultation on Incontinence Questionnaire module on UI symptoms (ICIQ-UI) short form (0-21 overall score, with higher scores indicating more sever symptoms)

  3. urinary symptoms and degree to which UI-associated symptoms are troubling or bothersome

    Time frame: immediately after the 12-week intervention (POST)

    urinary symptoms and degree to which UI-associated symptoms are troubling or bothersome, evaluated using the International Consultation on Incontinence Questionnaire module on UI symptoms (ICIQ-UI) short form (0-21 overall score, with higher scores indicating more sever symptoms)

  4. urinary symptoms and degree to which UI-associated symptoms are troubling or bothersome

    Time frame: 6 months after the end of the 12-week intervention (FOLLOW-UP)

    urinary symptoms and degree to which UI-associated symptoms are troubling or bothersome, evaluated using the International Consultation on Incontinence Questionnaire module on UI symptoms (ICIQ-UI) short form (0-21 overall score, with higher scores indicating more sever symptoms)

  5. Changes in urinary symptoms and degree to which UI-associated symptoms are troubling or bothersome

    Time frame: at recruitment (PRE1), just before the intervention (PRE2), immediately after the 12-week intervention (POST), 6 months after the end of the 12-week intervention (FOLLOW-UP)

    urinary symptoms and degree to which UI-associated symptoms are troubling or bothersome, evaluated using the International Consultation on Incontinence Questionnaire module on UI symptoms (ICIQ-UI) short form (0-21 overall score, with higher scores indicating more sever symptoms)

  6. bladder, bowel, pelvic organ prolapse and sexual function symptoms and degree to which these symptoms are troubling or bothersome

    Time frame: at recruitment (PRE1)

    bladder, bowel, pelvic organ prolapse and sexual function symptoms and degree to which these symptoms are troubling or bothersome, evaluated using the Australian Pelvic Floor Questionnaire (APFQ) (0-45 score for bladder symptoms, 0-34 score for bowel symptoms, 0-15 score for pelvic organ prolapse symptoms, and 0-21 score for sexual function symptoms, with higher scores indicating more severe symptoms)

  7. bladder, bowel, pelvic organ prolapse and sexual function symptoms and degree to which these symptoms are troubling or bothersome

    Time frame: just before the intervention (PRE2)

    bladder, bowel, pelvic organ prolapse and sexual function symptoms and degree to which these symptoms are troubling or bothersome, evaluated using the Australian Pelvic Floor Questionnaire (APFQ) (0-45 score for bladder symptoms, 0-34 score for bowel symptoms, 0-15 score for pelvic organ prolapse symptoms, and 0-21 score for sexual function symptoms, with higher scores indicating more severe symptoms)

  8. bladder, bowel, pelvic organ prolapse and sexual function symptoms and degree to which these symptoms are troubling or bothersome

    Time frame: immediately after the 12-week intervention (POST)

    bladder, bowel, pelvic organ prolapse and sexual function symptoms and degree to which these symptoms are troubling or bothersome, evaluated using the Australian Pelvic Floor Questionnaire (APFQ) (0-45 score for bladder symptoms, 0-34 score for bowel symptoms, 0-15 score for pelvic organ prolapse symptoms, and 0-21 score for sexual function symptoms, with higher scores indicating more severe symptoms)

  9. bladder, bowel, pelvic organ prolapse and sexual function symptoms and degree to which these symptoms are troubling or bothersome

    Time frame: 6 months after the end of the 12-week intervention (FOLLOW-UP)

    bladder, bowel, pelvic organ prolapse and sexual function symptoms and degree to which these symptoms are troubling or bothersome, evaluated using the Australian Pelvic Floor Questionnaire (APFQ) (0-45 score for bladder symptoms, 0-34 score for bowel symptoms, 0-15 score for pelvic organ prolapse symptoms, and 0-21 score for sexual function symptoms, with higher scores indicating more severe symptoms)

  10. Changes in bladder, bowel, pelvic organ prolapse and sexual function symptoms and degree to which these symptoms are troubling or bothersome

    Time frame: at recruitment (PRE1), just before the intervention (PRE2), immediately after the 12-week intervention (POST), 6 months after the end of the 12-week intervention (FOLLOW-UP)

    bladder, bowel, pelvic organ prolapse and sexual function symptoms and degree to which these symptoms are troubling or bothersome, evaluated using the Australian Pelvic Floor Questionnaire (APFQ) (0-45 score for bladder symptoms, 0-34 score for bowel symptoms, 0-15 score for pelvic organ prolapse symptoms, and 0-21 score for sexual function symptoms, with higher scores indicating more severe symptoms)

  11. UI-related quality of life

    Time frame: at recruitment (PRE1)

    UI-related quality of life, evaluated using the International Consultation on Incontinence Questionnaire module on Lower Urinary Tract Symptoms quality of life (ICIQ-LUTS QoL) (19-76 overall score with greater values indicating increased impact on quality of life)

  12. UI-related quality of life

    Time frame: just before the intervention (PRE2)

    UI-related quality of life, evaluated using the International Consultation on Incontinence Questionnaire module on Lower Urinary Tract Symptoms quality of life (ICIQ-LUTS QoL) (19-76 overall score with greater values indicating increased impact on quality of life)

  13. UI-related quality of life

    Time frame: immediately after the 12-week intervention (POST)

    UI-related quality of life, evaluated using the International Consultation on Incontinence Questionnaire module on Lower Urinary Tract Symptoms quality of life (ICIQ-LUTS QoL) (19-76 overall score with greater values indicating increased impact on quality of life)

  14. UI-related quality of life

    Time frame: 6 months after the end of the 12-week intervention (FOLLOW-UP)

    UI-related quality of life, evaluated using the International Consultation on Incontinence Questionnaire module on Lower Urinary Tract Symptoms quality of life (ICIQ-LUTS QoL) (19-76 overall score with greater values indicating increased impact on quality of life)

  15. Changes in UI-related quality of life

    Time frame: at recruitment (PRE1), just before the intervention (PRE2), immediately after the 12-week intervention (POST), 6 months after the end of the 12-week intervention (FOLLOW-UP)

    UI-related quality of life, evaluated using the International Consultation on Incontinence Questionnaire module on Lower Urinary Tract Symptoms quality of life (ICIQ-LUTS QoL) (19-76 overall score with greater values indicating increased impact on quality of life)

  16. UI-associated costs

    Time frame: at recruitment (PRE1)

    UI-associated costs, using the adapted Dowell-Bryant Incontinence Cost Index (DBICI) questionnaire

  17. UI-associated costs

    Time frame: immediately after the 12-week intervention (POST)

    UI-associated costs, using the adapted Dowell-Bryant Incontinence Cost Index (DBICI) questionnaire

  18. UI-associated costs

    Time frame: 6 months after the end of the 12-week intervention (FOLLOW-UP)

    UI-associated costs, using the adapted Dowell-Bryant Incontinence Cost Index (DBICI) questionnaire

  19. technology self-efficacy

    Time frame: at recruitment (PRE1)

    technology self-efficacy, evaluated using the Online Technologies Self-efficacy Scale (OTSES) questionnaire (30-120 overall score, with higher scores indicating lower level of technology self-efficacy)

  20. technology self-efficacy

    Time frame: immediately after the 12-week intervention (POST)

    technology self-efficacy, evaluated using the Online Technologies Self-efficacy Scale (OTSES) questionnaire (30-120 overall score, with higher scores indicating lower level of technology self-efficacy)

  21. technology self-efficacy

    Time frame: 6 months after the end of the 12-week intervention (FOLLOW-UP)

    technology self-efficacy, evaluated using the Online Technologies Self-efficacy Scale (OTSES) questionnaire (30-120 overall score, with higher scores indicating lower level of technology self-efficacy)

  22. UI related self-efficacy

    Time frame: at recruitment (PRE1)

    UI related self-efficacy, evaluated using the geriatric self-efficacy scale (GES) (0-120 overall score, with higher scores indicating higher level of self-efficacy related to urinary incontinence)

  23. UI related self-efficacy

    Time frame: immediately after the 12-week intervention (POST)

    UI related self-efficacy, evaluated using the geriatric self-efficacy scale (GES) (0-120 overall score, with higher scores indicating higher level of self-efficacy related to urinary incontinence)

  24. UI related self-efficacy

    Time frame: 6 months after the end of the 12-week intervention (FOLLOW-UP)

    UI related self-efficacy, evaluated using the geriatric self-efficacy scale (GES) (0-120 overall score, with higher scores indicating higher level of self-efficacy related to urinary incontinence)

  25. Pelvic floor muscles related self-efficacy

    Time frame: at recruitment (PRE1)

    Pelvic floor muscles related self-efficacy, evaluated using the Broome's self-efficacy scale (14 items with responses ranging 0-100 for part A and 9 items with responses ranging 0-100 for part B; an overall mean self-efficacy score is calculated, also ranging 0-100)

  26. Pelvic floor muscles related self-efficacy

    Time frame: immediately after the 12-week intervention (POST)

    Pelvic floor muscles related self-efficacy, evaluated using the Broome's self-efficacy scale (14 items with responses ranging 0-100 for part A and 9 items with responses ranging 0-100 for part B; an overall mean self-efficacy score is calculated, also ranging 0-100)

  27. Pelvic floor muscles related self-efficacy

    Time frame: 6 months after the end of the 12-week intervention (FOLLOW-UP)

    Pelvic floor muscles related self-efficacy, evaluated using the Broome's self-efficacy scale (14 items with responses ranging 0-100 for part A and 9 items with responses ranging 0-100 for part B; an overall mean self-efficacy score is calculated, also ranging 0-100)

  28. Vaginal atrophy symptoms

    Time frame: at recruitment (PRE1)

    Vaginal atrophy symptoms, evaluated using the Atrophy Symptom Questionnaire (ASQ) (0-15 overall score, with higher scores indicating higher severity of vaginal atrophy symptoms)

  29. Vaginal atrophy symptoms

    Time frame: immediately after the 12-week intervention (POST)

    Vaginal atrophy symptoms, evaluated using the Atrophy Symptom Questionnaire (ASQ) (0-15 overall score, with higher scores indicating higher severity of vaginal atrophy symptoms)

  30. Vaginal atrophy symptoms

    Time frame: 6 months after the end of the 12-week intervention (FOLLOW-UP)

    Vaginal atrophy symptoms, evaluated using the Atrophy Symptom Questionnaire (ASQ) (0-15 overall score, with higher scores indicating higher severity of vaginal atrophy symptoms)

  31. Patient reported improvement and satisfaction

    Time frame: immediately after the 12-week intervention (POST)

    Patient reported improvement and satisfaction, evaluated using the patient global impression of improvement (PGI-I) index, a single-item tool to capture perceived satisfaction with treatment: "satisfied" (does not need other treatments); "unsatisfied" (would like another treatment for UI)

  32. Patient reported improvement and satisfaction

    Time frame: 6 months after the end of the 12-week intervention (FOLLOW-UP)

    Patient reported improvement and satisfaction, evaluated using the patient global impression of improvement (PGI-I) index, a single-item tool to capture perceived satisfaction with treatment: "satisfied" (does not need other treatments); "unsatisfied" (would like another treatment for UI)

  33. Feasibility/Acceptability (reach)

    Time frame: through intervention completion, for 12 weeks

    Reach aspect of feasibility/acceptability, evaluated using attendance to weekly sessions

  34. Feasibility/Acceptability (fidelity)

    Time frame: through intervention completion, for 12 weeks

    Fidelity aspect of feasibility/acceptability, evaluated using the integrity of the GROUP program elements delivered by the physiotherapist during each session (checklist)

  35. Feasibility/Acceptability (dose)

    Time frame: through intervention completion, for 12 weeks

    Dose aspect feasibility/acceptability, evaluated using adherence to home exercises (exercises journal)

  36. Feasibility/Acceptability (perceived usability of the technology)

    Time frame: immediately after the 12-week intervention (POST)

    Perceived usability of the technology from the patients' experience as an aspect of feasibility/acceptability, evaluated using the System Usability Scale (SUS) (0-100 overall score, with higher scores indicating a higher usability)

  37. Feasibility/Acceptability (perceived usability of the technology)

    Time frame: 6 months after the end of the 12-week intervention (FOLLOW-UP)

    Perceived usability of the technology from the patients' experience as an aspect of feasibility/acceptability, evaluated using the System Usability Scale (SUS) (0-100 overall score, with higher scores indicating a higher usability)

  38. Potential challenges and satisfaction with the program from the patients' perspective

    Time frame: immediately after the intervention (POST)

    Potential challenges and satisfaction with the program from the patients' perspective, evaluated during focus groups or interviews using an interview guide developed from the seven dimensions of the Theoretical Framework of Acceptability (TFA), three of the five Consolidated Framework for Implementation Research (CFIR) domains and additional open-ended questions on satisfaction

Other outcomes

  1. Cognitive function

    Time frame: at recruitment (PRE1)

    Cognitive function, evaluated using the Mini-Mental State Examination (MMSE) (0-30 overall score, with scores of 24 and over indicating a normal cognitive function)

  2. Cognitive function

    Time frame: at recruitment (PRE1)

    Cognitive function, evaluated using the Montreal Cognitive Assessment (MoCA) (0-30 overall score, with scores of 26 and over indicating a normal cognitive function)

  3. Sociodemographic characteristics

    Time frame: at recruitment (PRE1)

    Sociodemographic characteristics, evaluated using a home-made questionnaire recording age, weight, height, living situation, marital status, education, annual income, gynecological and medical history, medication and hormones prescriptions, smoking status, along with the Questionnaire for female Urinary Incontinence Diagnosis (QUID) to determine UI type

  4. Signs of vaginal atrophy

    Time frame: at recruitment (PRE1)

    Signs of vaginal atrophy, observed during a gynecological evaluation, using the vaginal atrophy index (VAI) (6-15 overall score, with lower scores indicating more severe symptoms of vaginal atrophy)

  5. Pelvic floor muscle function

    Time frame: at recruitment (PRE1)

    Gynecological evaluation of pelvic floor muscle function, using the Laycock's PERFECT score (PERFECT is an acronym with P = power of the pelvic floor muscle contraction, measured with the modified Oxford 6-point scale: 0=no contraction, 1=flicker, 2=weak, 3=moderate, 4=good, and 5=strong; E = endurance of the pelvic floor muscle contraction, measured from 0 to 10 seconds, R = repetitions, measured from 0 to 10 contractions, F = fast contractions, measured as the number of fast maximal contractions over a period of 10 seconds, E = elevation of the posterior vaginal wall during the pelvic floor muscle contraction (yes/no), C = co-contraction of the lower abdominal muscles during the pelvic floor muscle contraction (yes/no), T = timing, with the presence of synchronous involuntary contraction of pelvic floor muscles on coughing (yes/no))

  6. Signs and severity of pelvic prolapse

    Time frame: at recruitment (PRE1)

    Signs and severity of pelvic prolapse, observed during a gynecological evaluation, using the Baden-Walker prolapsus score (0-4 overall score, with higher scores indicating a higher severity)

Sponsors and collaborators

Lead sponsor

Université de Montréal

Other

Collaborators

  • Centre de Recherche de l'Institut Universitaire de Geriatrie de Montreal
  • Réseau québécois de recherche sur le vieillissement (RQRV)

Registry information

Official study title

Feasibility, Acceptability and Effects of a Tele-rehabilitation Pelvic Floor Muscle Training Group Program for Urinary Incontinence in Older Women

Important dates

Study start
2021
Primary completion
2022
Study completion
2026
First posted
Jan 10, 2022
Registry last updated
Apr 23, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.